SCHEMBL10320596

SCHEMBL10320596

CC(C)(C)OC(=O)N1C[C@H]2CC(NC(=O)OCc3ccccc3)C[C@H]2C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.52
JAK2 O60674 1/20 0.51
JAK1 P23458 1/20 0.51
L3MBTL1 Q9Y468 2/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
CTSK P43235 1/20 0.48
TSHR P16473 1/20 0.47
NR1H2 P55055 1/20 0.47
DPP4 P27487 4/20 0.45
DPP7 Q9UHL4 4/20 0.45
EPHX1 P07099 1/20 0.45
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
ACHE P22303 2/20 0.44
KCNH2 Q12809 2/20 0.44
ABCB1 P08183 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10450036 1.00 HSD11B1 (0.52) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL27345269 1.00 HSD11B1 (0.52) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL31045669 0.94 HSD11B1 (0.53) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL10321562 0.93 JAK2 (0.62) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL11957600 0.93 JAK2 (0.62) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL12323283 0.93 JAK2 (0.62) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL10450103 0.93 JAK2 (0.62) HSD11B1JAK2JAK1L3MBTL1KMT2A
SCHEMBL29232309 0.91 ALDH1A1 (0.53) HSD11B1L3MBTL1KMT2AALDH1A1GAA
SCHEMBL17135691 0.87 KMT2A (0.49) HSD11B1L3MBTL1KMT2AALDH1A1GAA
SCHEMBL17135699 0.87 KMT2A (0.49) HSD11B1L3MBTL1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014119-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC (US) 2026-01-15 US disclosed
EP-4652161-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS Uppthera, Inc. (KR) 2025-11-26 EP disclosed
EP-4554934-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-05-21 EP disclosed
WO-2024155112-A1 2,4-DIANILINOPYRIMIDINE-BASED AURORA-A KINASE SELECTIVE DEGRADATION INDUCING COMPOUNDS UPPTHERA, INC. (KR) 2024-07-25 WO disclosed
WO-2024015503-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2024-01-18 WO disclosed
US-20120184543-A1 DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014119-A1 EMOPAMIL-BINDING PROTEIN INHIBITORS AND USES THEREOF EBP, EBPL, ELP1 HSD11B1 741/4885JAK2 4314/4885JAK1 4721/4885
US-20120184543-A1 DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF PLK2, PLK3, DMPK HSD11B1 948/4885JAK2 645/4885JAK1 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.